Voyageur Pharmaceuticals Ltd. is advancing a comprehensive strategy to establish a vertically integrated supply chain for barium and iodine contrast media drugs, targeting critical vulnerabilities in the diagnostic imaging sector. The global market for these pharmaceuticals is projected to grow from US$6.77 billion in 2024 to US$13.86 billion by 2033 according to Research Contrast, creating significant demand pressures. With barite classified as a critical mineral by the U.S. Geological Survey, Voyageur's approach encompasses the entire value chain from mineral discovery to finished product manufacturing to ensure supply security and competitive production costs.
The company is currently focused on completing two bankable feasibility studies that underpin this strategy: the Voyageur Radiology Iodine & Barium Drug Manufacturing Project and the Bayer Iodine Project. These projects represent foundational steps toward establishing a resilient, North American–based supply chain capable of supporting growing global demand. Voyageur's barium strategy centers on the Frances Creek project, which hosts an indicated and inferred mineral resource of 132,000 tonnes of pharmaceutical grade barium sulfate with purity averaging 98.8% BaSO4, exceeding pharmaceutical grade requirements of 97.5%.
Voyageur has already generated approximately C$32,000 in initial contrast product sales through five Health Canada approved barium products manufactured with Alberta Veterinary Laboratories, establishing commercial validation. Sales and pricing data from Canadian and international markets are being incorporated into the ongoing Frances Creek barium BFS, which the company expects to deliver in the second half of 2026. A preliminary economic assessment completed earlier valued the FC barium contrast project with a NPV of $344M, as detailed in a news release dated January 11, 2022.
Regulatory pathways for U.S. market entry are progressing, with FDA approval for barium and iodine contrast media expected to follow an 18 to 24-month review process, potentially enabling market entry as soon as mid to late 2027. Voyageur has completed first drafts of all barium FDA submission documents and formally commenced the approval process in February 2026 via the 505(b)(2) regulatory pathway. The company plans to advance a generic iodine FDA license in the second half of 2026, further strengthening its pharmaceutical portfolio.
For iodine contrast media, Voyageur is independently advancing a prefeasibility study that integrates the Mueller iodine extraction process with the Streamline iodine drug manufacturing platform. The project leverages iodine-rich brine sourced from oil and gas operations and water disposal companies in the United States, targeting 35 million doses per year of iodine contrast drug production. The combined processes are expected to significantly lower manufacturing costs for iodine drugs.
The Bayer Iodine Project represents another key component of Voyageur's strategy, with US$2.35 million in funding focused on completing a BFS. This collaboration began with the signing of an LOI with Bayer on December 20, 2024, and represents an important step in Voyageur's mission to become the first domestic producer of iodine contrast in the United States. Subject to successful completion of the Bayer BFS, the companies may consider advancing the project into a second phase under an offtake-linked production financing arrangement where Bayer would provide capital financing while Voyageur would operate and manage the project.
Voyageur is engaging with a global engineering company to complete the final two BFS, positioning the company to establish secure, large-scale North American supply of essential contrast media drugs. Upon completion, Voyageur will have finalized the economics and plant design to vertically produce iodine and barium contrast media drugs, potentially becoming the only vertically integrated radiology drug company in the marketplace. The company is actively reviewing financial options to fund future capital expenditures, targeting construction to commence in 2027 based on finalized feasibility studies.
